Genenta Science Spa Stock Investor Sentiment

GNTA Stock  USD 4.78  0.01  0.21%   
About 55% of Genenta Science's investor base is interested to short. The analysis of the overall investor sentiment regarding Genenta Science SpA suggests that many traders are impartial. The current market sentiment, together with Genenta Science's historical and current headlines, can help investors time the market. In addition, many technical investors use Genenta Science SpA stock news signals to limit their universe of possible portfolio assets.
  

Genenta Science Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Genenta Science can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
over a year ago at news.google.com         
CEL-SCI down 6 percent on 1.35M public offering - Seeking Alpha
Google News at Macroaxis
over a year ago at globenewswire.com         
Genenta Announces Fiscal Year 2022 Financial Results and Annual Report on Form 20-F Filing
Macroaxis News: globenewswire.com
over a year ago at news.google.com         
Anixa Biosciences Breast Cancer Vaccine Candidate Has 15 percent Probability of Success Amid Updated...
Google News at Macroaxis
over a year ago at news.google.com         
Sherwin-Williams Has A Pretty Healthy Balance Sheet - Simply Wall St
Google News at Macroaxis
over a year ago at finance.yahoo.com         
Genenta Announces Extension of License Agreement with Ospedale San Raffaele to All Solid Tumor Indic...
Yahoo News
over a year ago at news.google.com         
Brainstorm wins FDA AdCom meeting for ALS therapy NASDAQ ... - Seeking Alpha
Google News at Macroaxis
over a year ago at news.google.com         
Nogin Full Year 2022 Earnings EPS Beats Expectations - Yahoo Finance
Google News at Macroaxis
over a year ago at news.google.com         
Returns On Capital At UnitedHealth Group Have Hit The Brakes - Yahoo Finance
Google News at Macroaxis
over a year ago at news.google.com         
Pyxis starts dosing in early stage study of cancer therapy PYX-201 - Seeking Alpha
Google News at Macroaxis
over a year ago at news.google.com         
Genenta Science S p A Regulation FD Disclosure - Form 6-K - Marketscreener.com
Google News at Macroaxis
over a year ago at news.google.com         
AbCheck develops microfluidics tech for antibody discovery under ... - Seeking Alpha
Google News at Macroaxis
over a year ago at news.google.com         
Is Applied Industrial Technologies, Inc.s Latest Stock ... - Yahoo Finance
Google News at Macroaxis
over a year ago at news.google.com         
Cidara stock slumps 15 percent on common stock, preferred shares ... - Seeking Alpha
Google News at Macroaxis
over a year ago at finance.yahoo.com         
FDA Grants Orphan Drug Designation to Temferon for Treatment of Glioblastoma Multiforme
Yahoo News
over a year ago at news.google.com         
DermTech Q4 2022 Earnings Preview - Seeking Alpha
Google News at Macroaxis
Far too much social signal, news, headlines, and media speculation about Genenta Science that are available to investors today. That information is available publicly through Genenta media outlets and privately through word of mouth or via Genenta internal channels. However, regardless of the origin, that massive amount of Genenta data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Genenta Science news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Genenta Science relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Genenta Science's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Genenta Science alpha.

Genenta Science Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
AlTi Global Inc. Acquires Shares of 200,288 Genenta Science S.p.A. - MarketBeat
09/26/2024
2
Genenta Secures Approval for Innovative Trial for Metastatic Renal Cell Cancer
10/02/2024
3
Genenta Science S.p.A.s market cap rose US46m last week individual investors who hold 55 percent profited and so did insiders
10/11/2024
4
Genenta Science S.p.A. Quarterly 10-Q Report - Quartzy
11/12/2024
5
Genenta Science Shares Down 4.9 percent - Whats Next - MarketBeat
11/20/2024

Complementary Tools for Genenta Stock analysis

When running Genenta Science's price analysis, check to measure Genenta Science's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Genenta Science is operating at the current time. Most of Genenta Science's value examination focuses on studying past and present price action to predict the probability of Genenta Science's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Genenta Science's price. Additionally, you may evaluate how the addition of Genenta Science to your portfolios can decrease your overall portfolio volatility.
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing